TELFAST HD Tablet

TELFAST 180 is indicated for the relief of symptoms associated with chronic idiopathic urticaria in adults and children 12 years of age and older.

Dosage

Adults and children aged 12 years and over.

The recommended dose of Telfast 180mg is one tablet once daily.

Children under 12 years of age. The efficacy and safety of fexofenadine hydrochloride has not been studied in children under 12.

in patients with known hypersensitivity to any of its ingredients.

In controlled clinical trials the most commonly reported adverse events were headache, drowsiness, nausea, dizziness and fatigue.

Fexofenadine does not undergo hepatic biotransformation and therefore will not interact with other drugs through hepatic mechanisms.

Erythromycin or Ketoconazole: Co-administration of fexofenadine hydrochloride with erythromycin or ketoconazole has been found to result in a 2-3 times increase in the level of fexofenadine in plasma. The changes were not accompanied by any effects on the QT interval and were not associated with any increase in adverse events compared to the drugs given singly.

Animal studies have shown that the increase in plasma levels of fexofenadine observed after coadministration of erythromycin or ketoconazole, appears to be due to an increase in gastrointestinal absorption and either a decrease in biliary excretion or gastrointestinal secretion, respectively.

Omeprazole: No interaction between fexofenadine and omeprazole was observed.

Aluminium and magnesium hydroxide containing antacids: The administration of an antacid containing aluminium and magnesium hydroxide gels 15 minutes prior to fexofenadine hydrochloride caused a reduction in bioavailability, most likely due to binding in the gastrointestinal tract. It is advisable to leave 2 hours between administration of fexofenadine hydrochloride and aluminium and magnesium hydroxide containing antacids.

There is no experience with fexofenadine hydrochloride in pregnant women. As with other medications fexofenadine hydrochloride should not be used during pregnancy unless the expected benefit to the patient outweighs any possible risk to the foetus.

There are no data on the content of human milk after administering fexofenadine hydrochloride. However, when terfenadine was administered to nursing mothers fexofenadine was found to cross into human breast milk. Therefore fexofenadine hydrochloride is not recommended for mothers breast feeding their babies.

There is only limited data in the elderly and renally or hepatically impaired patients. Fexofenadine hydrochloride should be administered with care in these special groups.

Fexofenadine hydrochloride is a non-sedating H1 antihistamine.